Project Sage Oldco (OTCPK:SIEN.Q) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

SIEN.Q Stoklara Genel Bakış

Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products in the United States and internationally.

Şirket hakkında

SIEN.Q temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	0/6
Temettüler	0/6

Ödüller

Earnings have grown 11% per year over the past 5 years

Risk Analizi

Does not have a meaningful market cap ($299K)

Highly volatile share price over the past 3 months

Negative shareholders equity

Hissedarlar geçen yıl sulandırıldı

+ 1 daha fazla risk

Project Sage Oldco, Inc. Rakipler

Surgalign Holdings

OTCPK:SRGA.Q

US$165.3k

Procyon

OTCPK:PCYN

US$2.2m

InVitro International

OTCPK:IVRO

US$1.6m

Vycor Medical

OTCPK:VYCO

US$2.5m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Project Sage Oldco
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.025
52 Haftanın En Yüksek Seviyesi	US$4.94
52 Haftanın En Düşük Seviyesi	US$0.019
Beta	1.97
11 Aylık Değişim	0%
3 Aylık Değişim	-86.26%
1 Yıllık Değişim	-99.18%
33 Yıllık Değişim	-99.97%
5 Yıllık Değişim	-99.95%
Halka arzdan bu yana değişim	-99.99%

Son Haberler & Güncellemeler

Recent updates

FDA approves Sientra’s breast implant product for breast augmentation, reconstruction

Jul 06

Sientra (NASDAQ:SIEN) Is Carrying A Fair Bit Of Debt

Apr 16

Is Sientra (NASDAQ:SIEN) Using Too Much Debt?

Jan 06

Hissedar Getirileri

	SIEN.Q	US Medical Equipment	US Pazar
7D	-37.3%	-1.1%	0.4%
1Y	-99.2%	20.8%	32.6%

Getiri vs. Endüstri: SIEN.Q underperformed the US Medical Equipment industry which returned -1.4% over the past year.

Getiri vs Piyasa: SIEN.Q underperformed the US Market which returned 20.5% over the past year.

Fiyat Oynaklığı

Is SIEN.Q's price volatile compared to industry and market?
SIEN.Q volatility
SIEN.Q Average Weekly Movement	97.8%
Medical Equipment Industry Average Movement	8.5%
Market Average Movement	6.4%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: SIEN.Q's share price has been volatile over the past 3 months.

Zaman İçindeki Volatilite: SIEN.Q's weekly volatility has increased from 56% to 98% over the past year.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2003	304	Ron Menezes	sientra.com

Project Sage Oldco, Inc. Temel Bilgiler Özeti

Project Sage Oldco'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
SIEN.Q temel i̇stati̇sti̇kler
Piyasa değeri	US$298.94k
Kazançlar(TTM)	-US$59.33m
Gelir(TTM)	US$90.30m

0.0x

P/S Oranı

0.0x

F/K Oranı

SIEN.Q aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
SIEN.Q gelir tablosu (TTM)
Gelir	US$90.30m
Gelir Maliyeti	US$52.28m
Brüt Kâr	US$38.02m
Diğer Giderler	US$97.35m
Kazançlar	-US$59.33m

Son Raporlanan Kazançlar

Sep 30, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-4.96
Brüt Marj	42.11%
Net Kâr Marjı	-65.71%
Borç/Özkaynak Oranı	-183.5%

SIEN.Q uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

SIEN.Q Stoklara Genel Bakış

Ödüller

Risk Analizi

Project Sage Oldco, Inc. Rakipler

OTCPK:SRGA.Q

US$165.3k

OTCPK:PCYN

US$2.2m

OTCPK:IVRO

US$1.6m

OTCPK:VYCO

US$2.5m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Second Amended Liquidation Plan Approved for Sientra, Inc.

Second Amended Combined Joint Reorganization Plan and Disclosure Statement Filed by Sientra, Inc.

First Motion for Exclusivity Period Extension Filed by Sientra, Inc.

Joint Reorganization Plan and Disclosure Statement Filed by Sientra, Inc.

Reorganization Plan and Disclosure Statement Filed by Sientra, Inc.

The Nasdaq Stock Market to Delist the Common Stock of Sientra

Recent updates

Second Amended Liquidation Plan Approved for Sientra, Inc.

Second Amended Combined Joint Reorganization Plan and Disclosure Statement Filed by Sientra, Inc.

First Motion for Exclusivity Period Extension Filed by Sientra, Inc.

Joint Reorganization Plan and Disclosure Statement Filed by Sientra, Inc.

Reorganization Plan and Disclosure Statement Filed by Sientra, Inc.

The Nasdaq Stock Market to Delist the Common Stock of Sientra

Sientra, Inc. announced delayed annual 10-K filing

Sientra, Inc. announced delayed annual 10-K filing

Sientra, Inc.(OTCPK:SIEN.Q) dropped from NASDAQ Composite Index

DIP Financing Approved for Sientra, Inc.

Motion for Asset Sale Filed by Sientra, Inc.

Sientra, Inc. Filed for Bankruptcy

Sientra, Inc. Filed for Bankruptcy

Sientra Receives Non-Compliance Notice from Nasdaq

Consensus EPS estimates fall by 15%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Market cap size

Sientra, Inc. Provides Revenue Guidance for the Third Quarter of 2023

Sientra, Inc. Revises Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Sientra, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Sientra, Inc. Appoints Alexander W. Casdin to the Company’s Board of Directors, Effective June 15, 2023

Sientra Announces FDA-Clearance of Next Generation Allox2 Pro Tissue Expander

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Sientra, Inc. Provides Earnings Guidance for the Full Year of 2023

Fewer Investors Than Expected Jumping On Sientra, Inc. (NASDAQ:SIEN)

Full year 2022 earnings: EPS misses analyst expectations

Sientra, Inc. Announces Launch of Viality, Novel Fat Transfer System

Insider recently bought US$933k worth of stock

Price target decreased to US$2.08

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Sientra, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Sientra, Inc. has completed a Follow-on Equity Offering in the amount of $29.217384 million.

Sientra slides 18% on proposes stock offering

Sientra, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2022

Sientra refinances convertible debt at heavy premiums, sees Q3 revenue in-line

Sientra Receives Written Notice from the Listing Qualifications Department of Nasdaq

Sientra Receives Regulatory Approval to Market Breast Implants in Saudi Arabia

Sientra gets regulatory nod to market breast implants in Saudi Arabia

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Sientra, Inc. Revises Revenue Guidance for the Year 2022

Sientra GAAP EPS of -$0.29 misses by $0.06, revenue of $21.5M misses by $2.26M

Sientra, Inc. to Report Q2, 2022 Results on Aug 11, 2022

FDA Approves Sientra’s Low Plus Profile Projection Breast Implant

FDA approves Sientra’s breast implant product for breast augmentation, reconstruction

Sientra, Inc.(NasdaqGS:SIEN) dropped from Russell 2000 Dynamic Index

Price target decreased to US$6.33

Sientra, Inc. Provides Earnings Guidance for the Year 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$6.83

Sientra, Inc. to Report Q1, 2022 Results on May 12, 2022

Sientra, Inc., Annual General Meeting, Jun 09, 2022

Price target decreased to US$7.67

Sientra (NASDAQ:SIEN) Is Carrying A Fair Bit Of Debt

Consensus EPS estimates fall by 31%

Price target decreased to US$10.60

Sientra, Inc. Provides Preliminary Unaudited Financial Results for the Fourth Quarter and Full Year Ended December 31, 2021

Is Sientra (NASDAQ:SIEN) Using Too Much Debt?